Blackstone closed its inaugural royalty and structured credit-focused life sciences fund with $1.6 billion in investor commitments.
The Blackstone Life Sciences Yield fund was the largest first-time fund of this nature, according to officials at the $881 billion alternative investment firm. The strategy centers on post-approval, commercial-stage opportunities and complements Blackstone’s Life Sciences business, which invests in late-stage product development and is housed in Blackstone’s $261 billion private equity portfolio.
“Blackstone Life Sciences aim to invest across the full lifecycle of innovative medicines and medical technologies . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.
Monthly subscriptions and discounted corporate plans for up to 100 members also available.